Systemic sclerosis: The future is CD56-bright.
Systemic sclerosis: The future is CD56-bright.
复制标题
DOI：
10.1038/nrrheum.2016.168
复制
发表时间：
2016-11-01
期刊：
影响因子：
--
通讯作者：
Barranco, Caroline
中科院分区：
文献类型：
--
作者：
Barranco, Caroline
新的数据表明，自然杀伤（NK）细胞和自然杀伤T（NKT）样细胞的持续超活化可能有助于系统性硬化症（SSc）患者中观察到的异常先天免疫系统反应。“免疫系统的这些变化在疾病实际发作前几年就存在于个体中，并且可能代表了在纤维化过程发生之前阻止纤维化过程的机会之窗，”该研究的通讯作者玛尔塔科苏强调。研究人员发现了对Toll样受体（TLR）的失调反应，在树突状细胞和一个突出的I型干扰素签名在全血与SSc患者，特别是那些在这种疾病的最早阶段。“这一重点使我们将兴趣扩展到CD56+ NK和NKT样细胞群体，并探索它们的激活程度，不仅在疾病的早期阶段（纤维化实际发生之前），而且在临床前SSc中，”Cossu评论道。
Persistent hyperactivation of natural killer (NK) cells and natural killer T (NKT)-like cells might contribute to the aberrant innate immune system responses seen in individuals with systemic sclerosis (SSc), new data suggest.“These changes in the immune system are present in individuals years before the actual onset of disease, and could represent a window of opportunity to stop the fibrotic process before it occurs,” highlights Marta Cossu, the study's corresponding author.In previous work, the researchers identified a deregulated response to Toll-like receptors (TLRs) in dendritic cells and a prominent type I interferon signature in whole blood from patients with SSc, especially those in the earliest stages of this disease.“That focus led us to expand our interest to the CD56+ NK and NKT-like cell populations, and to explore the degree of their activation, not only in the earliest phases of disease (before fibrosis actually occurs) but also in preclinical SSc,” comments Cossu.